Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

At the 20^th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows. The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker. Together they enable post-genomic molecular and cell biology research, with key insights into disease biology and biomarkers for next-gen molecular diagnostics and drug discovery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311088724/en/

Bruker's Immunopeptidomics Workflow (Graphic: Business Wire)

The advances featured at US HUPO include improved machine-learning de novo sequencing (Novor V2.0), a novel high-performance monitoring digital-twin software (TwinScape), the new glyco-PASEF method for high-sensitivity glycopeptide analysis, and access to Spectronaut 18 for users of Bruker ProteoScape, a GPU-powered software for real-time 4D proteomics, now with access to library-free searches by Biognosys directDIA.

A. Advancing Cancer Immunotherapy Research

Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling. Novor v2.0, developed in collaboration with Rapid Novor Inc., was trained on >1,400,000 spectra mapping to >150,000 HLA peptides for research on small amounts of patient material derived from fine needle biopsies.

Dr. Juliane Walz, Professor of Peptide-based Immunotherapy and Medical Director for Translational Immunology at Universitätsklinikum Tübingen in Germany commented: “Our research focuses on the field of immunology and the development of novel peptide-based immunotherapy concepts for tumor and infectious diseases. Bruker’s trapped ion mobility separation combination with time-of-flight mass spectrometry enables immunopeptidomics with high speed and sensitive detection of HLA-presented peptides. Applying this technology, we have expanded the benign reference immunopeptidome databases with >150,000 HLA peptides. This allows us to confidently define tumor-associated antigens to fast-track immunotherapy development.”